PHARMAC reportedly has rejected funding for breast cancer drug

23 April 2019 - A breast cancer support group has been told that PHARMAC has rejected funding for the drug ...

Read more →

AbbVie expands immunology portfolio in the U.S. with FDA approval of Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis

23 April 2019 - AbbVie today announced that the U.S. FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of ...

Read more →

ICER's growing impact on drug pricing and reimbursement

17 April 2019 - The Institute for Clinical and Economic Review is sometimes called America's `NICE,’ referring to the National ...

Read more →

Top-down government efforts to corral drug prices will fail

23 April 2019 - Americans pay a lot for pharmaceuticals, and politicians of all stripes are offering prescription drug price-relief ...

Read more →

Ending drug rebates will not reduce drug prices

22 April 2019 - There are many reasons why drug prices are so high, beginning with the fact that it ...

Read more →

Canadians will wait longer for new medicines if Health Canada gets its way

23 April 2019 - The intention is to lower prices; the net result will likely be longer wait times before new ...

Read more →

PHARMAC rejects own experts' view on breast cancer drug

23 April 2019 - PHARMAC has refused funding for Kadcyla, an important drug that has recently had a high media ...

Read more →

Pharma lobby nears spending records with drug prices under fire

23 April 2019 - Drug makers, groups disclose first-quarter spending increases. ...

Read more →

Additional embargo period following revised CDEC recommendations

17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...

Read more →

FDA permits marketing of first medical device for treatment of ADHD

19 April 2019 - The U.S. FDA today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder.  ...

Read more →

Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?

23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines.  ...

Read more →

Intensity Therapeutics receives fast track designation from U.S. FDA for development of INT230-6 as treatment for relapsed or metastatic triple negative breast cancer

17 April 2019 - Intensity Therapeutics today announced that the U.S. FDA has granted fast track designation to the Company’s ...

Read more →

FDA approves Merck’s Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for patients with advanced renal cell carcinoma

22 April 2019 - Approval based on results of KEYNOTE-426, where Keytruda in combination with axitinib reduced the risk of death ...

Read more →

US FDA approves Duaklir Pressair (aclidinium/formoterol) for patients with chronic obstructive pulmonary disease

17 April 2019 - Only twice-daily LAMA /LABA in the United States with COPD exacerbation data included in its prescribing information. ...

Read more →

More than 1 million Americans have lost health insurance since 2016

19 April 2019 - More than 1 million Americans have lost health insurance coverage since 2016, according to a new ...

Read more →